TYRA

Tyra Biosciences, Inc. (TYRA) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP platform to design small molecule drug candidates for targeted oncology and genetically defined conditions. This report covers the quarterly period ended September 30, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the nine months ended September 30, 2025, increased by $25.2 million compared to the same period in 2024, driven primarily by higher R&D and G&A expenses.
• R&D Expense Growth: R&D expenses increased by $16.8 million year-over-year (YTD). This was driven by a $13.0 million increase in clinical start-up and enrollment activities for the BEACH301 (achondroplasia), SURF302 (bladder cancer), and SURF431 (TYRA-430) trials, alongside ongoing Chemistry, Manufacturing, and Controls (CMC) activities.
• G&A Expense Growth: G&A expenses increased by $5.0 million YTD, primarily due to higher personnel costs and a $3.3 million increase in non-cash stock-based compensation.
• Decline in Interest Income: Other income decreased by $3.4 million YTD due to lower interest rates and reduced balances in cash and marketable securities.
• Cash Position: Total cash, cash equivalents, and marketable securities decreased from $347.5 million at December 31, 2024, to $274.9 million at September 30, 2025, reflecting operational burn and net cash outflows from operations.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($274.9 million) are sufficient to fund operating expenses and capital expenditures through at least 2027.
• Clinical Milestones:
  • BEACH301 (Achondroplasia): First child dosed in August 2025; interim safety sentinel cohort results expected in H2 2026.
  • SURF302 (NMIBC): First patient dosed in June 2025; initial 3-month complete response data expected in H1 2026.
  • SURF303 (UTUC): FDA cleared IND in October 2025; study initiation expected in 2026.
  • SURF431 (TYRA-430): Patient dosing commenced in April 2025.
• Capital Strategy: The company entered into a new "at-the-market" (ATM) Sales Agreement with TD Securities in May 2025 for up to $150.0 million. No shares have been sold under this agreement as of September 30, 2025.
• Risks: The company has never generated revenue and expects to incur significant losses for the foreseeable future. Future capital requirements depend on clinical trial outcomes, regulatory approvals, and the ability to raise additional funds. Failure to secure financing could force delays or termination of programs.

Key Facts for Investor Verification

• Burn Rate: Verify the sustainability of the current cash runway (~$275 million) against the accelerating R&D spend ($74.7 million YTD) and the timeline to potential revenue.
• Clinical Enrollment: Monitor patient enrollment rates and safety data for the BEACH301 and SURF302 trials, as these are critical near-term value drivers.
• Capital Raising: Track utilization of the new $150 million ATM facility and any potential need for additional equity financing before 2027.
• Stock-Based Compensation: Note the significant non-cash expense ($20.4 million YTD) and the remaining unrecognized cost of $71.5 million, which will impact future earnings.
• Regulatory Status: Confirm the initiation timeline for the SURF303 study following the October 2025 IND clearance.